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Abstract
 Purpose—Diabetes is the leading cause of new cases of blindness among adults aged 20–74 
years within the United States. The Innovative Network for Sight Research group (INSIGHT) 
designed the Diabetic Eye Screening Study (DESS) to examine the feasibility and short-term 
effectiveness of non-mydriatic diabetic retinopathy (DR) screening for adults with diabetes in 
community-based settings.
 Methods—Study enrollment began in December 2011 at four sites: an internal medicine clinic 
at a county hospital in Birmingham, Alabama; a Federally-qualified community healthcare center 
in Miami-Dade County, Florida; a university-affiliated outpatient pharmacy in Philadelphia, 
Pennsylvania; and a medical home in Winston-Salem, North Carolina. People 18 years or older 
with previously diagnosed diabetes were offered free DR screening using non-mydriatic retinal 
photography that was preceded by a brief questionnaire addressing demographic information and 
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previous eye care use. Visual acuity was also measured for each eye. Images were evaluated at a 
telemedicine reading center by trained evaluators using the National Health System DR grading 
classification. Participants and their physicians were sent screening report results and telephoned 
for a follow-up survey 3 months post-screening to determine whether participants had sought 
follow-up comprehensive eye care and their experiences with the screening process.
 Results—Target enrollment at each site was a minimum of 500 persons. Three of the four sites 
met this enrollment goal.
 Conclusion—The INSIGHT/DESS is intended to establish the feasibility and short-term 
effectiveness of DR screening using non-mydriatic retinal photography in persons with diabetes 
who seek services in community-based clinic and pharmacy settings.
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 Introduction
Diabetes is the leading cause of new cases of blindness among adults aged 20–74 years in 
the United States.1–4 In 2005–2008, 4.2 million (28.5%) of Americans with diabetes aged 40 
years or older had diabetic retinopathy (DR) and of these, 655,000 (4.4%) had advanced DR 
that could lead to severe vision loss.1 The number of people with DR is expected to increase 
more than 3-fold by 2050, creating an immense and costly public health problem.4–7 
Successful management of DR includes early diagnosis, tight glycemic and blood pressure 
control, and medical treatment.8–12 Clinical trials demonstrating the efficacy of these 
interventions led the American Academy of Ophthalmology, the American Diabetes 
Association and the American Optometric Association to recommend annual dilated fundus 
examinations to reduce the risk of vision loss.13–15 Despite the risk of vision loss, only 50–
60% of people with diabetes, and even fewer in some low-income populations, follow this 
recommendation, and about 50% of persons are diagnosed too late for treatment to be 
optimally effective.16–18
Screening for DR using a non-invasive, non-mydriatic (no dilating drops needed) fundus 
camera has become an accepted screening method for people with diabetes in many parts of 
the world.19–21 These cameras provide digital fundus images that are graded for the presence 
of DR. The timely identification of ocular disease in people with diabetes can aid in 
successful management of DR and prevention of vision loss. Those who screen positive 
(have findings that are not normal) can then be referred for a comprehensive dilated eye 
examination and management.
The Innovative Network for Sight Research (INSIGHT) Diabetic Eye Screening Study 
(DESS) was designed to examine the feasibility and effectiveness of non-invasive, non-
mydriatic DR screening for people with diabetes in community-based clinic and pharmacy 
settings, specifically primary care health clinics and pharmacies. The study targeted 
communities with large, underserved, minority populations at high risk of DR. The 
community-based approach to screening was chosen for its potential to reach and screen a 
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larger population of those with diabetes than screenings performed in eye care provider 
offices or in other tertiary care settings.
 Materials and methods
 Study design overview
The purpose of the INSIGHT/DESS was to conduct a prospective, multi-site evaluation of 
the feasibility of DR screening with non-mydriatic retinal imaging in adults with diabetes in 
a variety of primary care clinic and pharmacy settings serving minority, high-risk 
populations. At baseline, we administered a questionnaire, measured presenting distance 
visual acuity, and performed non-mydriatic ocular imaging. Images were read at a 
telemedicine reading center, and results were mailed to patients and their primary care 
physicians. Three months after screening results were made available to participants, and 
participants were contacted by telephone for a follow-up questionnaire to evaluate their 
experience with the screening process and to determine subsequent eye care use. The tenets 
of the Declaration of Helsinki were upheld throughout this study and all participating centers 
received site-specific ethics approval. Written informed consent included consent to contact 
participants’ primary care physician.
 Specific aims
The INSIGHT/DESS had five specific aims: (1) to determine the average number of 
individuals screened on a monthly basis; (2) to determine the rate of DR (by eye and 
individual), and corresponding severity; (3) to determine the rate of individuals who show 
signs of additional ocular pathology including cataract, glaucoma, or corneal conditions; (4) 
to determine the rate of individuals who schedule recommended follow-up eye care; and, (5) 
to determine individuals’ self-reported experiences with the screening process.
 Organizational structure
The INSIGHT network includes four institutions, the University of Alabama at Birmingham 
(UAB), the University of Miami, Wills Eye Hospital (WEH), and Johns Hopkins University 
with Wake Forest University, collaborating with the Centers for Disease Control and 
Prevention (CDC) Vision Health Initiative in the Division of Diabetes Translation. The 
executive committee, which guided the study, consisted of the four principal investigators 
plus a CDC scientific collaborator. The Administrative and Coordinating Center and 
Telemedicine Department were based at WEH and the Data Management and Analysis 
Center was based at UAB.
 Study setting and recruitment
DR screening was conducted at four locations beginning in December 2011. Major 
eligibility criteria included adults 18 years or older with previously diagnosed diabetes (type 
1 or 2) who resided in one of the community locations. The recruitment process and unique 
setting of each site is described below and summarized in Table 1. All sites were chosen to 
target high-risk, minority populations with diabetes.
Murchison et al. Page 3













 Site 1: University of Alabama at Birmingham—The UAB site was based in the 
Internal Medicine Clinic of Cooper Green Mercy Health System in Birmingham, Alabama. 
The health system, located in the most populated county in Alabama, is Alabama’s only 
county-owned, community health system with outpatient and urgent care clinics, offering 
care to all residents of Jefferson County regardless of ability to pay. The majority of patients 
have no health insurance. DR screening for the study was performed as part of usual care for 
diabetic patients who presented to the clinic. The vast majority of patients who seek care 
through the health system are African American.
 Site 2: University of Miami—The University of Miami site was the Jessie Trice 
Community Health Center, a federally-qualified community healthcare center serving the 
uninsured or underinsured in Miami-Dade County, Florida. Participants, who had to be 
residents of Miami-Dade County, were recruited via flyers in the community, flyers posted 
at the community center, and referral by local physicians. English, Spanish and Haitian 
Creole speaking patients were eligible at this site.
 Site 3: Wills Eye Hospital—The WEH site was an outpatient pharmacy in 
Philadelphia, Pennsylvania, located within the Jefferson Health System used primarily by 
patients and employees of Thomas Jefferson University. Pharmacy personnel directed 
individuals picking up diabetic medication to the screening location. Family practice 
physicians with offices in the same building as the pharmacy referred individuals to the 
study after being made aware of the program. Flyers were posted in the pharmacy and were 
given to family practice physicians to increase recruitment. Additionally, advertisements 
were placed in local newspapers. English and Spanish speaking individuals were eligible at 
this site.
 Site 4: Johns Hopkins University—The initial site for John Hopkins University was 
a pharmacy in a rural town in New Mexico serving a population primarily of Hispanic or 
American Indian ethnicity. Due to inability to recruit patients, the site was changed to the 
Wake Forest School of Medicine-affiliated Downtown Health Plaza (DHP) located within 
downtown Winston-Salem, North Carolina, primarily serving low-income residents of the 
surrounding area. The DHP includes primary and specialty-care clinics as well as an onsite 
pharmacy. DHP physicians and pharmacy staff serving individuals with diabetes referred 
individuals to the screening study.
 Sample size
The target sample size for the INSIGHT/DESS was a minimum of 500 at each site. The 
sample size was selected to allow for comparison of feasibility and effectiveness between 
study sites.
 Study questionnaire and visual acuity
Following informed consent, a research staff member administered a questionnaire to each 
participant. Collected variables included participant contact information, sex, age, race, 
ethnicity, insurance status, time since diabetes diagnosis, primary care physician (PCP) visit 
in past year, hemoglobin A1c, timing of last dilated eye exam, smoking status, permission to 
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contact PCP, request for eye care provider contact information, request for scheduling 
assistance, and history of cataract surgery. Walk-in distance visual acuity was measured for 
each eye with the participant’s current distance correction (if worn) using the Titmus V2 
vision screener (Sperian Protection Optical Inc, Chester, VA, USA).
 Ocular imaging
Following the questionnaire and walk-in distance visual acuity testing, ocular imaging was 
performed. A chin rest and forehead rest were used to position the individual in front of the 
camera. To minimize interference from room lighting, either a drape covering the 
participant’s head or darkened room was used during the imaging. Trained technicians used 
a non-mydriatic Nidek Model AFC-230 camera (Nidek Inc, Fremont, CA, USA) with auto-
focus in accordance with the camera’s standard operating instructions. Three photos were 
taken of each eye (anterior segment, nasal fundus, and temporal fundus), for a total of six 
images per participant. If images were blurry or the participant blinked, additional images 
were taken until a satisfactory image was obtained. Images were generated using NavisLite 
software (Nidek Inc) and uploaded to a Health Insurance Portability and Accountability Act 
(HIPPA)-compliant secure website administered by the WEH Telemedicine Reading Center. 
Technicians were prompted to record a number of demographic and health variables into the 
online database at the time of photography.
 Image grading
At the WEH Telemedicine Reading Center, a HIPPA-compliant proprietary software 
program was used for image reading and report generation for each site. The study’s grading 
system for DR was based on the National Health System DR grading classification system 
and is reproduced in Table 2 22 We selected this system because it is widely used in 
telemedicine screening programs. Other ocular pathology was recorded as present or absent 
based on external and fundus images. Noted abnormalities included hypertensive changes, 
cotton wool spots, branch retinal vein occlusion, central retinal vein occlusion, branch 
retinal artery occlusion, central retinal artery occlusion, vitreous opacity, nevus, macular 
degeneration, scar, cataract, corneal changes, and cup-to-disc ratio >0.6. Certified image 
readers at the WEH Telemedicine Reading Center determined preliminary grades within 48 
hours of image upload to the WEH secure website. All images showing signs of DR or other 
ocular pathology were further reviewed by an ophthalmologist at the Reading Center.
Based on recommendations from the American Academy of Ophthalmology for DR follow-
up, screening reports were automatically generated as determined by degree of DR (Table 
2).13 Patients with any of the six images deemed unreadable due to poor photographic 
quality (focus, location, contrast, etc.) were advised to follow-up with repeat imaging or an 
eye care provider due to unreadable images.
 Notification of findings and referrals
All study participants were notified of their examination results, and results were also sent to 
participants’ primary care provider if they had requested this at the time of screening. For 
individuals whose reports recommended prompt referral to an eye care provider due to DR 
or maculopathy (grades R2, R3 and M in Table 2), a site-specific research coordinator 
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telephoned the participant within 48 hours of receiving the report to advise them of the 
recommendation. The coordinator also offered the participant assistance with scheduling an 
appointment with an eye care provider. Up to five attempts were made to reach the 
participant by phone. A letter was also mailed to the participant and the participant’s 
primary care provider (when consent was previously given) with the results and 
recommendations of the screening.
For participants whose reports recommended normal (non-urgent) referral or follow-up 
(grades R0, R1, P and U on Table 2), a letter was sent to the participants describing the 
screening results. For abnormal screening results designated for normal referral (grades R1, 
P and U), the letter encouraged the participant to seek an appointment for a dilated eye 
examination “within the next few months.” For normal screening results (grade R0), the 
letter encouraged the participant to seek an appointment for a dilated eye examination on an 
annual basis.
 Telephone follow-up questionnaire
Site-specific research staff administered a follow-up questionnaire by telephone 
approximately 3 months after the screening results were distributed to each participant. The 
follow-up time frame was selected to give participants ample opportunity to follow-up with 
their primary care physician and/or eye care provider, should they choose to do so. The 
questionnaire addressed participants’ experience with the screening process, whether they 
would be willing to pay for the screening in the future, their recommendations for improving 
the screening, what they were told about the outcomes of their screening, and follow-up eye 
care use or plans for eye care use since the screening. At least five telephone-call attempts 
were made to the participant before the participant was designated as unable to be reached 
for questionnaire administration.
 Data management
At the time of the initial retinal imaging and questionnaire, a unique numerical identification 
was generated for each participant. Each site entered participant data from screening forms 
and follow-up questionnaires into a secure web-based data entry system stored at the Data 
Management and Analysis Center. Each site implemented technician training and quality 
control procedures to ensure data were correctly entered in this master database.
All images with their corresponding identification number and all fields from the DR 
screening report were uploaded and securely stored at the Reading Center. Once enrollment 
closed and all reports were generated, the report results were electronically transmitted to 
the Data Management and Analysis Center for merging with data from the screening forms 
and follow-up questionnaires. Site-specific databases were made available at each site to 
facilitate analysis of site-specific data. A network-wide analysis of data was performed to 
address network-wide aims.
 Results
Target enrollment at each site was a minimum of 500 persons. Three of the sites achieved or 
exceeded this minimum while the remaining site enrolled 180 persons. Details for each site 
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can be found in Table 1. The majority of patients participating were female (63.1%) and of a 
racial/ethnic minority (88%). While there were site differences in populations, the mean age 
at each site was similar at 53–55 years. Overall, 12% of patients had one or more images 
that were deemed ungradable.
Overall, recruitment by site tended toward older median age and female population (Table 
3). Additionally, African Americans made up the largest racial/ethnic group at all sites 
except 1, which had a larger Hispanic/Latino population. All sites recruited more under/
uninsured population than the county demographic average. The reported rate of dilated eye 
examinations within the past year by site ranged from 25.5–52.8%.
 Quality assurance
Several measures were implemented to ensure quality of the data collection and image 
reading. Staff members and telemedicine specialists trained technicians at each site to 
administer the questionnaire and to operate the camera. Staff members observed as 
technicians administered the questionnaire and photography on a semi-weekly basis. To 
ensure that data were correctly entered, a double-entry system was used.
To ensure consistent grading quality, 10% of images labeled normal by the readers were 
randomly selected and reviewed by ophthalmologists to ensure correct classification of 
normal images. No images labeled normal by the image readers were found to have signs of 
pathology. To evaluate intra-grader reliability (repeat grading by the same person), 138 
patients (828 images, both normal and with pathology) were randomly selected for re-
evaluation. The proportion of these images found to have DR mirrored that of the overall 
study population, with roughly 25% of individuals having some level of DR (Table 4). The 
image reader who graded the original images re-graded these selected images, masked to her 
previous grades, with a minimum of 3 months between her first and second grade. The 
kappa coefficient was used to determine the level of agreement between the original and 
second grades, corrected for agreement by chance alone. The intra-grader kappa coefficient 
for DR findings was 0.72, (95% confidence interval, CI, 0.62–0.83) with 88.8% agreement. 
Metrics on variability of each grader over time was not performed, as all readers had years 
of experience.
The same procedure and images were used to evaluate inter-grader reliability. The inter-
grader kappa coefficient for DR findings was 0.62 (95% CI 0.51–0.73) with agreement of 
84.1%.
 Discussion
The INSIGHT/DESS represents a uniquely designed, multi-center study evaluating diabetic 
eye screening using a non-mydriatic camera in community-based settings in the US. 
Strengths of the study include the standardization of the screening protocol and 
questionnaire, use of a single central reading center, and inclusion of multiple geographic 
locations and racial/ethnic populations, and different community-based settings (e.g. clinics, 
pharmacy). Quality assurance measures allowed for accurate data entry and image reading. 
Locating the study within different clinical and pharmacy settings will allow for evaluation 
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of feasibility and effectiveness across different care settings. The urban settings proved to be 
more feasible, in this study, than the more rural screening site. Both outpatient clinics and 
the outpatient pharmacy setting were able to recruit and screen the desired number of 
patients over the study time frame. However, the out-patient clinic venues had the greatest 
success. The sites primarily seemed to recruit from the underserved, as reflected in the low 
health care coverage compared to the counties’ coverage. We hypothesize that these urban 
settings could potentially sustain long-term screening and follow-up tele-ophthalmic diabetic 
evaluations. In a more rural setting, perhaps a different approach would better serve the 
community and provide better use of resources.
Limitations of the study include its reliance on participant self-reporting information such as 
time since diabetes diagnosis and eye care use, the potential of poor image quality leading to 
missed diagnosis of pathology, and loss to follow-up for the telephone survey. Data on 
qualified individuals who declined screening were not collected, nor do we know what 
proportion of individuals with diabetes in these communities had access to the study. It is 
possible that the study may not be generalizable to other regions, racial populations, or care 
settings. While based on the National Health Service grading classification system and 
American Academy of Ophthalmology follow-up recommendations, the study’s grading and 
recommendation methodology have not been previously validated.
In collaboration with the CDC Vision Health Initiative, the INSIGHT network is evaluating 
the effectiveness and feasibility of diabetic eye screenings in primary care clinics and 
pharmacies, targeting a diverse, medically underserved portion of the diabetic population 
that often does not undergo annual DR screening. The DESS will provide information on the 
prevalence and severity of diabetic eye disease and additional ocular pathology for 
individuals in these community-based clinic and pharmacy settings. Results of the study can 
potentially be used by public health researchers and clinicians in studies, as well as used on 
a large scale for underserved populations.
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Table 1
Overview of each site in the Innovative Network for Sight Research Diabetic Eye Screening Study, United 
States.
Site Camera placement State Patients recruited, n Majority race/ethnicity
University of Alabama at 
Birmingham
Internal medicine clinic at county 
hospital
Alabama 612 African American
University of Miami Community health center Florida 622 Hispanic/Latino
Wills Eye Hospital Outpatient pharmacy at university Pennsylvania 500 Caucasian
Johns Hopkins University Outpatient medical home North Carolina 180 African American
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Table 2
Innovative Network for Sight Research Diabetic Eye Screening Study image grade, description, and 
recommendations based on the National Health System Grading Classification System and American 
Academy of Ophthalmology Recommendations, United States.
Grade Description Recommendation
R0 No DR Re-evaluate in 12 months with either eye care specialist or 
photographic screening
None
Isolated cotton wools spots (≥1) in the absence of any microaneurysm 
or hemorrhage
R1 Background DR Refer to eye care provider
≥1 microaneurysm(s)
≥1 retinal hemorrhage(s)
Any exudates caused by DR
R2 Pre-proliferative DR Refer to ophthalmologist promptly
Intra-retinal microvascular abnormality
Venous beading
Venous loop or reduplication
Multiple deep, round or blot hemorrhages
R3 Proliferative DR Refer to ophthalmologist promptly
New vessels on the disc
New vessels elsewhere
Pre-retinal or vitreous hemorrhage
Pre-retinal fibrosis with or without tractional retinal detachment due to 
DR
M Maculopathy Refer to ophthalmologist promptly
Exudate within 1DD of the center of the fovea
Circinate or group of exudates within the macula
Any microaneurysm or hemorrhage within 1DD of the center of the 
fovea only if associated with a best visual acuity 20/40 or worse
P Photocoagulation Refer to eye care provider
Focal/grid to macula
Peripheral scatter
U Unclassifiable/ungradable Refer to eye care provider
Due to poor photographic location, focus, or contrast
DR, diabetic retinopathy; DD, disc diameter.
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Table 4
Final results from fundus image subset evaluated for quality control, Innovative Network for Sight Research 
Diabetic Eye Screening Study, United States.
Diabetic retinopathy diagnosis
n (%)
(N = 138 patients)
No DR 208 (75.4)
Background DR 36 (13.0)
Pre-proliferative DR 2 (0.7)
Proliferative DR 4 (1.5)
Ungradable 26 (9.4)
DR, Diabetic retinopathy.
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